-
公开(公告)号：US20240336640A1
公开(公告)日：2024-10-10
申请号：US18744642
申请日：2024-06-16
IPC分类号： C07F9/09 , A61K31/80 , C07C43/196 , C08G65/34
CPC分类号： C07F9/09 , A61K31/80 , C07C43/196 , C08G65/34
摘要： The present invention relates to inositol derivatives comprising two or more cyclohexanolpentakisester moieties linked by a common central linker and their use in therapy or prevention of a condition related to pathological crystallization. The invention further relates to useful intermediates in the synthesis of the compound of the invention.
-
公开(公告)号：US20240239780A1
公开(公告)日：2024-07-18
申请号：US18556128
申请日：2022-04-21
发明人： Wilm BUHR , Aris KALOGERAKIS , Klaus-Daniel UMLAND , Stefan REIM , Vania MANOLOVA , Patrick ALTERMATT , Anna FLACE
IPC分类号： C07D413/14 , A61K31/4439 , A61K31/444 , A61K31/473 , A61K31/4745 , A61K31/496 , A61K31/5377 , A61K45/06 , C07D471/04 , C07D491/056
CPC分类号： C07D413/14 , A61K31/4439 , A61K31/444 , A61K31/473 , A61K31/4745 , A61K31/496 , A61K31/5377 , A61K45/06 , C07D471/04 , C07D491/056
摘要： The invention relates to novel compounds of the general formula (I), which are characterized in that at least one of the groups A and B contains at least 3 rings, pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders leading to increased iron levels or increased iron absorption, and/or iron overload.
-
公开(公告)号：US20240100074A1
公开(公告)日：2024-03-28
申请号：US18262591
申请日：2022-01-26
IPC分类号： A61K31/6615 , A61K9/00 , A61P39/00
CPC分类号： A61K31/6615 , A61K9/0004 , A61P39/00
摘要： The invention relates to a dosing schedule for an inositol polyphosphate oligo(ethylene glycol) compound, or its pharmaceutically acceptable salt used in the treatment or prevention of a disease associated with formation of, and/or tissue exposure to, calcium salt crystals. The drug compound is administered at an interval of one week.
-
公开(公告)号：US20220363675A1
公开(公告)日：2022-11-17
申请号：US17340692
申请日：2021-06-07
发明人： Franz Dürrenberger , Michael Burgert , Susanna Burckhardt , Wilm Buhr , Aris Kalogerakis , Stefan Reim , Vania Manolova , Susan Boyce , Christopher John Yarnold , Paula Pena , Jon Shepherd , Cristina Lecci , Richard Jarjes-Pike , John Scott
IPC分类号： C07D413/14 , A61K31/4184 , A61K31/427 , A61K31/4355 , A61K31/437 , A61K31/4375 , A61K31/4439 , A61K31/444 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/55 , C07D417/14 , C07D471/04 , C07D401/14 , C07D417/12 , A61K31/426 , A61K31/435 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K45/06 , C07D277/56 , A61P7/06 , A61P25/28 , A61P25/16 , A61P3/12 , C07D403/14 , C07D413/04 , C07D487/04
摘要： The invention relates to novel compounds of the general formula (I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
-
公开(公告)号：US20220054540A1
公开(公告)日：2022-02-24
申请号：US17416695
申请日：2019-12-20
摘要： The invention relates to intravenously administered ferric carboxymaltose for the use as a diuretic medicament, in particular for the treatment of congestion, or of congestion associated with impaired function of the heart and/or associated with deterioration of the function of the heart in a patient suffering from heart failure with iron deficiency or in a patient being iron deficient and at risk of developing heart failure.
-
公开(公告)号：US20210115163A1
公开(公告)日：2021-04-22
申请号：US17132652
申请日：2020-12-23
发明人： Peter Geisser , Erik Philipp , Walter Richle
IPC分类号： C08B30/18 , A61P7/06 , A61K31/295 , A61K31/718 , A61K33/26 , A61K45/06 , C08B31/18 , A61K47/61 , C08B37/00
摘要： A water soluble iron carbohydrate complex obtainable from an aqueous solution of iron(III) salt and an aqueous solution of the oxidation product of one or more maltrodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, a process for its production and a medicament for the treatment and prophylaxis of iron deficiency conditions.
-
公开(公告)号：US10738041B2
公开(公告)日：2020-08-11
申请号：US15768025
申请日：2016-10-21
发明人： Franz Dürrenberger , Wilm Buhr , Susanna Burckhardt , Michael Burgert , Aris Kalogerakis , Stefan Reim , Vania Manolova , Susan Boyce , Christopher John Yarnold , Paula Pena , Jon Shepherd , Cristina Lecci , Richard Jarjes-Pike , John Scott
IPC分类号： C07D413/14 , A61K31/427 , A61K31/437 , A61K31/444 , A61K31/501 , A61K31/506 , A61K31/55 , C07D417/12 , C07D471/04 , C07D401/14 , A61K31/426 , A61K31/435 , A61K31/497 , A61K45/06 , C07D277/56 , C07D403/14 , C07D413/04 , C07D487/04 , A61K31/4184 , A61K31/4355 , A61K31/4375 , A61K31/4439 , A61K31/4985 , A61K31/5377 , C07D417/14 , A61K31/4709 , A61K31/4725 , A61P7/06 , A61P25/28 , A61P25/16 , A61P3/12 , A61K31/16 , A61K31/4422 , A61K36/9066
摘要： The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
-
公开(公告)号：US20190263939A1
公开(公告)日：2019-08-29
申请号：US16389272
申请日：2019-04-19
发明人： Peter Geisser , Erik Philipp , Walter Richle
IPC分类号： C08B30/18 , A61K47/61 , C08B31/18 , C08B37/00 , A61K31/295 , A61K45/06 , A61K33/26 , A61K31/718
摘要： A water soluble iron carbohydrate complex obtainable from an aqueous solution of iron (III) salt and an aqueous solution of the oxidation product of one or more maltodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, process for its production and a medicament for the treatment and prophylaxis of iron deficiency conditions.
-
公开(公告)号：US20140364424A1
公开(公告)日：2014-12-11
申请号：US14310254
申请日：2014-06-20
发明人： Wilm Buhr , Susanna Burckhardt , Franz Dürrenberger , Felix Funk , Peter O. Geisser , Vincent A. Corden , Stephen M. Courtney , Graham Dawson , Tara Davenport , Mark Slack , Mark P. Ridgill , Christopher J. Yarnold , Susan Boyce , Albertus A. Ellenbroek
IPC分类号： C07D513/04 , A61K45/06 , C07D401/12 , C07D409/12 , C07D215/40
CPC分类号： C07D513/04 , A61K45/06 , C07D215/40 , C07D215/42 , C07D215/46 , C07D215/50 , C07D333/34 , C07D401/12 , C07D409/12 , C07D417/12
摘要： The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.
摘要翻译： 本发明涉及新型的铁调素拮抗剂，包含它们的药物组合物及其作为用于治疗铁代谢紊乱的药物的用途，特别是铁缺乏症和贫血，特别是与慢性炎症有关的贫血 疾病
-
公开(公告)号：US20220387371A1
公开(公告)日：2022-12-08
申请号：US17888115
申请日：2022-08-15
发明人： Peter Geisser , Erik Philipp , Walter Richle
IPC分类号： A61K31/295 , A61P7/06 , A61K31/718 , A61K33/26 , A61K45/06 , C08B31/18 , A61K47/61 , C08B30/18 , C08B37/00
摘要： A water soluble iron carbohydrate complex obtainable from an aqueous solution of iron(III) salt and an aqueous solution of the oxidation product of one or more maltrodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, process for its production and a medicament for the treatment and prophylaxis of iron deficiency conditions.
-
-
-
-
-
-
-
-
-
搜索结果
43 条记录 (耗时 0.031 秒)
